Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection

NCT04706468 is registered in ClinicalTrials.gov with TaiGen Biotechnology Co., Ltd. as lead sponsor.

NCT NCT04706468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04706468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2020
Completion date
February 15, 2022
Enrollment
202 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza virus infection